Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis by Kabirraaj Toor, Mark R. Middleton, Keith Chan, Adenike Amadi, Andriy Moshyk, Srividya Kotapati

Get full text

Societal preferences for adjuvant melanoma health states: UK and Australia by Mark R. Middleton, Michael B. Atkins, Kaitlan Amos, Peter Feng Wang, Srividya Kotapati, Javier Sabater, Kathleen Beusterien

Get full text

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma by Wolfram Samlowski, Nicholas J. Robert, Liwei Chen, Brad Schenkel, Catherine Davis, Andriy Moshyk, Srividya Kotapati, Tayla Poretta, Jeffrey S. Weber

Get full text

308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma by Dirk Schadendorf, Mark Middleton, Jeffrey Weber, Delphine Hennicken, Paolo Ascierto, Andriy Moshyk, Roberto Zoffoli, Anne Pieters, Adenike Amadi, Katrin Kupas, Srividya Kotapati

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma by Victoria Federico Paly, Murat Kurt, Lirong Zhang, Marcus O. Butler, Olivier Michielin, Adenike Amadi, Emma Hernlund, Helen M. Johnson, Srividya Kotapati, Andriy Moshyk, John Borrill

Get full text